Venus Medtech, a Chinese company that produces heart valve replacement devices, has raised HK$2.41 billion ($308 million) in an initial public offering (IPO) on the Hong Kong stock exchange on Tuesday, becoming the latest healthcare company to shore up investors’ confidence in the Asian financial hub.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
